Chiaki Kawanishi1, Stefan Lundgren, Hans Agren, Leif Bertilsson. 1. Department of Medical Laboratory Sciences and Technology, Division of Clinical Pharmacology, Karolinska Institutet, Huddinge University Hospital, 14186 Stockholm, Sweden. chiaki@med.yokohama-cu.ac.jp
Abstract
OBJECTIVE: Recent studies have revealed that genetic polymorphisms of cytochrome P(450) 2D6 (CYP2D6) are among the factors that determine the interindividual differences in the metabolism and response to antidepressants. We investigated the relationship between persistent mood disorders and the duplication of the CYP2D6 gene, which encodes an enzyme with increased activity. METHODS: We screened the prevalence of the CYP2D6 genotypes in 108 patients with persistent mood disorders using long polymerase chain reaction (PCR) and the real-time PCR methods. Clinical correlates with the genotypes were also analyzed. RESULTS: Among the 108 patients, 81 had failed to respond to antidepressants shown to be metabolized by CYP2D6. Of those 81, 8 had a CYP2D6 gene duplication (9.9%, 95% confidence interval 3.4-16.4%) which was higher than the 0.8-1.0% incidence previously observed in healthy Nordic Caucasians. The worst week scores of the Hamilton Depression Rating Scale were higher in the patients with the duplication compared with those without the duplication ( P=0.026, student's t-test). CONCLUSION: These results suggest that the CYP2D6 gene duplication is a possible factor that influences the development of persistence in patients with mood disorders probably by ultrarapid drug metabolism.
OBJECTIVE: Recent studies have revealed that genetic polymorphisms of cytochrome P(450) 2D6 (CYP2D6) are among the factors that determine the interindividual differences in the metabolism and response to antidepressants. We investigated the relationship between persistent mood disorders and the duplication of the CYP2D6 gene, which encodes an enzyme with increased activity. METHODS: We screened the prevalence of the CYP2D6 genotypes in 108 patients with persistent mood disorders using long polymerase chain reaction (PCR) and the real-time PCR methods. Clinical correlates with the genotypes were also analyzed. RESULTS: Among the 108 patients, 81 had failed to respond to antidepressants shown to be metabolized by CYP2D6. Of those 81, 8 had a CYP2D6 gene duplication (9.9%, 95% confidence interval 3.4-16.4%) which was higher than the 0.8-1.0% incidence previously observed in healthy Nordic Caucasians. The worst week scores of the Hamilton Depression Rating Scale were higher in the patients with the duplication compared with those without the duplication ( P=0.026, student's t-test). CONCLUSION: These results suggest that the CYP2D6 gene duplication is a possible factor that influences the development of persistence in patients with mood disorders probably by ultrarapid drug metabolism.
Authors: K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin Journal: Br J Clin Pharmacol Date: 1999-09 Impact factor: 4.335
Authors: A Wennerholm; I Johansson; A Y Massele; M Lande; C Alm; Y Aden-Abdi; M L Dahl; M Ingelman-Sundberg; L Bertilsson; L L Gustafsson Journal: Pharmacogenetics Date: 1999-12
Authors: L Bertilsson; M L Dahl; F Sjöqvist; A Aberg-Wistedt; M Humble; I Johansson; E Lundqvist; M Ingelman-Sundberg Journal: Lancet Date: 1993-01-02 Impact factor: 79.321
Authors: E Aklillu; I Persson; L Bertilsson; I Johansson; F Rodrigues; M Ingelman-Sundberg Journal: J Pharmacol Exp Ther Date: 1996-07 Impact factor: 4.030
Authors: Pedro López-Morales; Diego Flores-Funes; Elena González Sánchez-Migallón; Ramón José Lirón-Ruiz; José Luis Aguayo-Albasini Journal: J Gastrointest Surg Date: 2018-05-03 Impact factor: 3.452
Authors: Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li Journal: J Clin Pharmacol Date: 2010-01-15 Impact factor: 3.126